> Details

Gill, Tejpal; Stauffer, Patrick; Asquith, Mark; Laderas, Ted; Martin, Tammy M.; Davin, Sean; Schleisman, Matthew; Ramirez, Claire; Ogle, Kimberly; Lindquist, Ingrid; Nguyen, Justine; Planck, Stephen R.; Shaut, Carley; Diamond, Sarah; Rosenbaum, James T.; Karstens, Lisa

Axial spondyloarthritis patients have altered mucosal IgA response to oral and fecal microbiota

Reference
management

Bookmarks

Remove from
bookmarks

Share this on Whatsapp

Close

Bookmarks



You can manage bookmarks using lists, please log in to your user account for this.
  • Media type: E-Article
  • Title: Axial spondyloarthritis patients have altered mucosal IgA response to oral and fecal microbiota
  • Contributor: Gill, Tejpal; Stauffer, Patrick; Asquith, Mark; Laderas, Ted; Martin, Tammy M.; Davin, Sean; Schleisman, Matthew; Ramirez, Claire; Ogle, Kimberly; Lindquist, Ingrid; Nguyen, Justine; Planck, Stephen R.; Shaut, Carley; Diamond, Sarah; Rosenbaum, James T.; Karstens, Lisa
  • imprint: Frontiers Media SA, 2022
  • Published in: Frontiers in Immunology
  • Language: Not determined
  • DOI: 10.3389/fimmu.2022.965634
  • ISSN: 1664-3224
  • Keywords: Immunology ; Immunology and Allergy
  • Origination:
  • Footnote:
  • Description: <jats:p>Axial spondyloarthritis (axSpA) is an inflammatory arthritis involving the spine and the sacroiliac joint with extra-articular manifestations in the eye, gut, and skin. The intestinal microbiota has been implicated as a central environmental component in the pathogenesis of various types of spondyloarthritis including axSpA. Additionally, alterations in the oral microbiota have been shown in various rheumatological conditions, such as rheumatoid arthritis (RA). Therefore, the aim of this study was to investigate whether axSpA patients have an altered immunoglobulin A (IgA) response in the gut and oral microbial communities. We performed 16S rRNA gene (16S) sequencing on IgA positive (IgA<jats:sup>+</jats:sup>) and IgA negative (IgA<jats:sup>-</jats:sup>) fractions (IgA-SEQ) from feces (n=17 axSpA; n=14 healthy) and saliva (n=14 axSpA; n=12 healthy), as well as on IgA-unsorted fecal and salivary samples. PICRUSt2 was used to predict microbial metabolic potential in axSpA patients and healthy controls (HCs). IgA-SEQ analyses revealed enrichment of several microbes in the fecal (<jats:italic>Akkermansia</jats:italic>, <jats:italic>Ruminococcaceae</jats:italic>, <jats:italic>Lachnospira</jats:italic>) and salivary (<jats:italic>Prevotellaceae</jats:italic>, <jats:italic>Actinobacillus</jats:italic>) microbiome in axSpA patients as compared with HCs. Fecal microbiome from axSpA patients showed a tendency towards increased alpha diversity in IgA<jats:sup>+</jats:sup> fraction and decreased diversity in IgA<jats:sup>-</jats:sup> fraction in comparison with HCs, while the salivary microbiome exhibits a significant decrease in alpha diversity in both IgA<jats:sup>+</jats:sup> and IgA<jats:sup>-</jats:sup> fractions. Increased IgA coating of <jats:italic>Clostridiales Family XIII</jats:italic> in feces correlated with disease severity. Inferred metagenomic analysis suggests perturbation of metabolites and metabolic pathways for inflammation (oxidative stress, amino acid degradation) and metabolism (propanoate and butanoate) in axSpA patients. Analyses of fecal and salivary microbes from axSpA patients reveal distinct populations of immunoreactive microbes compared to HCs using the IgA-SEQ approach. These bacteria were not identified by comparing their relative abundance alone. Predictive metagenomic analysis revealed perturbation of metabolites/metabolic pathways in axSpA patients. Future studies on these immunoreactive microbes may lead to better understanding of the functional role of IgA in maintaining microbial structure and human health.</jats:p>
  • Access State: Open Access